Achieve Life Sciences ACHV Stock News

Achieve Life Sciences Inc (NASDAQ: ACHV) is rocketing in the market this morning, trading on premarket gains of more than 70%. While the company moved forward with a reverse stock split today, that has little to do with the move. Instead the gains seem to be associated with a patent that has been granted. Here’s what’s going on:

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

ACHV Stock Rockets On Granted Patent

In a press release issued this morning, Achieve Life Sciences said that the United States Patent and Trademark Office has granted it a new patent. The patent surrounds novel analogs of cytisinicline, a process for preparation, and use in the prevention or treatment of CNS and addictive disorders.

In the release, ACHV reminded investors that cytisinicline is a selective partial agonist of nicotine acetylcholine receptors (nAChRs). The drug was designed to fight nicotine addiction. However, nAChRs are involved in a wide range of phsioloigical functions.

In fact, it’s believed that the treatment may help with cognitive function, learning and memory, emotion and control of movement. In the release, the company said that the newly patented analogs provide it with the opportunity for selctive targeting of nAChRs in the brain in order to treat a number of conditions.

In fact, the company believes that the treatment may be effective not only as a smoking cessation aid, but also asn an option for Alzheimer’s disease, depression, anxiety, schizophrenia, epilepsy, Parkinson’s disease and addiction.

In a statement, Rick Stewart, Chairman and CEO at ACHV, had the following to offer:

While smoking cessation and nicotine addiction continue to be our primary focus, it is critically important that we continue to expand our intellectual property portfolio through patent extensions and future potential indications of cytisinicline.

This Is Big News

The news released by Achieve Life Sciences that was released this morning proved to be overwhelmingly positive. The new patent further strengthens IP, which is exciting in and of itself. However, the excitement goes far beyond that.

Most investors have looked at ACHV as a smoking cessation play. However, the patent shows that there’s potential for the company’s flagship candidate to treat a wide range of neurological conditions, making this a much more exciting value proposition.

With the news of the issued patent on the table, ACHV stock is one to watch closely.

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

Don’t Miss The Next big Story

Join our free mailing list below to receive real-time news alerts!

Subscribe Today!

* indicates required


LEAVE A REPLY

Please enter your comment!
Please enter your name here

This site uses Akismet to reduce spam. Learn how your comment data is processed.